Equities researchers at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a report released on Sunday. The firm set a “hold” rating on the stock.
TherapeuticsMD Stock Performance
TXMD stock opened at $1.69 on Friday. TherapeuticsMD has a fifty-two week low of $1.43 and a fifty-two week high of $3.15. The company’s 50 day moving average price is $1.76 and its 200 day moving average price is $1.93.
TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million during the quarter.
Hedge Funds Weigh In On TherapeuticsMD
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Further Reading
- Five stocks we like better than TherapeuticsMD
- Insider Trading – What You Need to Know
- The Average 401k Balance by Age Explained
- What is Put Option Volume?
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What Are the U.K. Market Holidays? How to Invest and Trade
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.